Coordinatore | ETHNIKO IDRYMA EREVNON
Organization address
address: Vassileos Constantinou Avenue 48 contact info |
Nazionalità Coordinatore | Greece [EL] |
Totale costo | 1˙008˙989 € |
EC contributo | 970˙300 € |
Programma | FP7-REGPOT
Specific Programme "Capacities": Research potential of Convergence Regions |
Code Call | FP7-REGPOT-2008-1 |
Funding Scheme | CSA-SA |
Anno di inizio | 2009 |
Periodo (anno-mese-giorno) | 2009-02-01 - 2012-01-31 |
# | ||||
---|---|---|---|---|
1 |
ETHNIKO IDRYMA EREVNON
Organization address
address: Vassileos Constantinou Avenue 48 contact info |
EL (ATHENS) | coordinator | 970˙300.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'EUROSTRUCT seeks to unravel the research potential of Structural Biology and Chemistry Group and Chemistry Group (SBCG) and the Institute of Organic and Pharmaceutical Chemistry (IOPC) of the National Hellenic Research Foundation by creating a centre of excellence in structural biology, in Greece, with emphasis on structure-based drug design and discovery. This can be achieved through setting up a state-of-the-art X-ray and computational facility, recruitment of experienced researchers, exchange of know-how and experience through trans-national two-way secondments of research staff, organization of workshops and conferences to facilitate knowledge transfer at regional, national and international level, and through dissemination and promotional activities. The EUROSTRUCT aims to build a critical mass of sustainable research capacity. In so doing, it will support researchers to tackle pressing health problems and deliver health benefits for people. The focus is on people and providing them with the research environment that they need in order to answer compelling questions about health and disease. The scientists participating in this application provide the appropriate scientific environment for high quality research engaged in the project. The EUROSTRUCT is intended to give recipients the freedom and flexibility to pursue new avenues of discovery and higher-risk research projects that hold potential for advancing significantly determination of three-dimensional structure of target proteins and structure-based drug discovery.'
Science is rapidly expanding humanity's ability to overcome disease with drugs that become more sophisticated by the hour. In the era of rational drug design a new EU centre of excellence has been established in Greece to undertake structure-based drug discovery efforts.